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Abstract
Genotoxic drugs constitute a major treatment modality for human
cancers; however, cancer cells’ intrinsic DNA repair capability often
increases the threshold of lethality and renders these drugs inef-
fective. The emerging roles of HDACs in DNA repair provide new
opportunities for improving traditional genotoxic drugs. Here, we
report the development and characterization of CY190602, a novel
bendamustine-derived drug with significantly enhanced anticancer
potency. We show that CY190602’s enhanced potency can be
attributed to its newly gained ability to inhibit HDACs. Using this
novel DNA/HDAC dual-targeting drug as a tool, we further explored
HDAC’s role in DNA repair. We found that HDAC activities are
essential for the expression of several genes involved in DNA
synthesis and repair, including TYMS, Tip60, CBP, EP300, and MSL1.
Importantly, CY190602, the first-in-class example of such DNA/
HDAC dual-targeting drugs, exhibited significantly enhanced anti-
cancer activity in vitro and in vivo. These findings provide ratio-
nales for incorporating HDAC inhibitory moieties into genotoxic
drugs, so as to overcome the repair capacity of cancer cells.
Systematic development of similar DNA/HDAC dual-targeting drugs
may represent a novel opportunity for improving cancer therapy.
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Introduction
A significant challenge for treating cancer is to enhance the efficacy
of existing drugs. Genotoxic drugs represent an important branch of
chemotherapy, which kill cancer cells by attacking cellular DNA.
Double-strand breaks (DSBs) resulting from such attacks are extre-
mely toxic, and one irreparable DSB is sufficient to induce cell death
(Jackson & Bartek, 2009). Despite such potent lethality, DNA
damage caused by anticancer drugs can be mitigated by cellular
DNA repair machinery, thus enabling some cancer cells to survive
and ultimately cause treatment failure. Drugs that inhibit DNA
repair, such as ATM and DNAPK inhibitors, have been intensely
investigated as potential means to improve chemotherapy (Hickson
et al, 2004; Helleday et al, 2008; Willmore et al, 2008; Jiang et al,
2009).
Nitrogen mustards are a major type of genotoxic anticancer
drugs. They work by attacking the N7 position of guanines on
opposing DNA strands, thereby causing DNA interstrand cross-
linkings (ICLs), which impede DNA replication forks and ultimately
cause DSBs. Several pathways exist in mammalian cells to repair
such damage, including the Fanconi anemia (FA) pathway, transle-
sional synthesis (TLS), and homologous recombination (HR)
(Knipscheer et al, 2009; Moldovan & D’Andrea, 2009). As a result,
nitrogen mustards are generally well tolerated by cancer cells.
Consequently, these drugs exhibit poor potency and limited treat-
ment success. An emerging approach is to suppress DNA repair in
order to enhance the efficacy of nitrogen mustards. Several lines of
evidence support the potential benefits of this approach. For exam-
ple, human patients with inherited deficiencies in FA pathway are
extremely sensitive to ICLs (Taniguchi & D’Andrea, 2006), and
tumors with mutations in the FA and HR pathways are hypersensi-
tive to ICL agents (Van der Heijden et al, 2005; Kennedy &
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D’Andrea, 2006; Byrski et al, 2010). Efforts to screen for inhibitors
of these repair pathways have yielded interesting results that may
benefit future anticancer therapy (Chirnomas et al, 2006).
Bendamustine, a nitrogen mustard originally synthesized in the
1960s, recently regained great clinical interest due to its beneficial
outcome in treating cancers (Keating et al, 2008; Cheson & Rummel,
2009; Knauf, 2009; Knauf et al, 2009; Garnock-Jones, 2010; Flinn
et al, 2014). The recently approved clinical indications for benda-
mustine include chronic lymphocytic leukemia (CLL), small
lymphocytic lymphoma (SLL), follicular lymphoma (FL), and
mantle-cell lymphoma (MCL). However, the efficacy of bendamus-
tine is limited by its poor drug potency. Therefore, bendamustine
represents an interesting candidate for drug optimization. Here, we
report our effort in developing and characterizing a more potent
bendamustine derivative and argue for a knowledge-based redesign
of existing genotoxic drugs.
Results
To improve bendamustine’s anticancer activity, a series of chemical
derivatives were synthesized. Among these, CY190602 (Fig 1A, and
referred to as CY thereafter) displayed 50- to 100-fold enhanced anti-
cancer toxicity. Treatment of the NCI60 cell lines (http://dtp.nci.
nih.gov/branches/btb/ivclsp.html) indicated a median growth inhib-
itor concentration (GI50) of 2.2 lM for CY, in contrast to the median
GI50 of 77 lM for bendamustine (Fig 1B). Of note, the GI50 for CY in
MEFs was 57 lM, about 20-fold higher than its average GI50
(3.2 lM) in NCI60 cell lines, suggesting that it may preferentially kill
cancer cells. Comparing the GI50 data of CY and bendamustine, such
a significant increase in drug potency is rather surprising, given that
CY differs from bendamustine only on its side chain, furthest away
from the purported nitrogen mustard functional group. To under-
stand CY’s mechanism of action, we utilized a functional genetic
approach for drug characterization (Jiang et al, 2011). Using this
approach, we previously reported that despite the dramatic increase
in potency, CY’s primary mode of cell death induction is still nitrogen
mustard-mediated DNA damage (Jiang et al, 2011).
To further understand how CY’s chemical modifications might
have resulted in such an increased potency, we synthesized
compound A (Fig 1A), in which the chloride atoms of CY’s nitrogen
mustard group were substituted with hydroxyl groups. As a result,
this compound retains the side chain modification of CY but lacks
ability to attack DNA. Study of this compound would therefore
enable us to focus on the side chain of CY. Consistent with the
notion that CY primarily kills cancer cells through its nitrogen
mustard group, compound A is very ineffective in killing cancer
cells, even at 200 lM concentration (Fig 1C). Interestingly, despite
its inability to kill cancer cells, compound A significantly synergized
with bendamustine to kill cancer cells (Fig 1C). This suggests that
compound A, and therefore the side chain of CY, is capable of
enhancing the activity of bendamustine. Moreover, although
compound A alone did not cause DNA damage, it significantly
increased the level of c-H2AX in bendamustine-treated cells
(Fig 1D). Taken together, these results suggest that although the
side chain group of CY is ineffective in killing cancer cells by itself,
it is capable of enhancing the action of CY’s nitrogen mustard group,
which may explain CY’s significantly increased anticancer potency.
Reexamination of CY’s side chain suggested that it conforms to
several rules of hydroxamic acid-based HDAC inhibitors (Suzuki
et al, 2005). First, aromatic rings of CY facilitate its interaction with
the surface of HDAC’s enzyme pocket. Second, CY’s 7-carbon side
chain mimics the length of a lysine residue, which is optimal for
inserting into HDAC’s enzyme pocket. Third, CY’s terminal
hydroxamic acid group serves to chelate the zinc atom inside
HDAC’s enzyme pocket, thereby inhibiting HDAC’s enzymatic activ-
ity. Indeed, when tested in cell-free HDAC activity assays, CY exhib-
ited an IC50 of 10–100 nM against HDAC1-6 in vitro (Fig 2A). In
intact cells, CY and Cpd A also induced significant accumulation of
acetylated histone H3 (Fig 2B and Supplementary Fig S1). In
contrast, bendamustine lacks both the proper side chain length and
the zinc-chelating hydroxamic acid group, which explains its inabil-
ity to inhibit HDAC (Fig 2A and 2B, Supplementary Fig S1). Lastly,
molecular docking of CY with the active sites of HDAC1 and
HDAC2’s X-ray structure suggested that CY is indeed capable of
fitting into HDAC active sites (Fig 2C).
Taken together, these results suggest that CY is a dual-targeting
drug, with both the DNA-damaging nitrogen mustard group and an
HDAC inhibitory moiety. To address whether CY’s HDAC inhibitory
activity is essential for its anticancer activity, we synthesized
compound B (Fig 1A), in which CY’s hydroxamic acid group was
substituted with a carboxylic acid group. Since carboxylic acid is far
less effective in chelating zinc, this compound harbors little HDAC
inhibitory activity (Fig 2D). We found that this compound is 10- to
20-fold less potent than CY (Fig 2E). This suggests that HDAC inhib-
itory group is essential for CY’s enhanced anticancer activity. Given
that both compound A (HDAC inhibitor only) and compound B
(nitrogen mustard only) are far inferior in their ability to kill cancer
cells, these results also suggested that these two functional groups
synergize with each other to confer significantly enhanced anti-
cancer potency. Such a synergy between nitrogen mustard and HDAC
inhibitors was confirmed by treating cells with bendamustine and
nontoxic dose of HDAC inhibitor Cpd A (Fig 2F and Supplementary
Fig S2). To our knowledge, CY represents the first-in-class example of
such DNA/HDAC dual-targeting drug that utilizes such intra-
molecular synergy.
Given that nontoxic doses of the HDAC inhibitor compound A
were capable of enhancing DNA damage caused by bendamustine
(Fig 2E), we hypothesized that the function of CY’s nitrogen
mustard group may be greatly potentiated by its HDAC inhibitory
group. Next, we performed several experiments to address the
mechanism of such potentiation.
Several recent publications argue for HDAC’s crucial involve-
ment in DNA repair (Miller et al, 2010; Robert et al, 2011).
Although several mechanisms have been proposed, the full range of
HDAC’s function in DNA repair remains undefined. Given HDAC’s
important roles in regulating gene expression, we asked whether
expressions of certain DNA repair genes are deregulated in CY-
treated cells. According to current model, there are several core
groups of ICL repair genes, including those participating in the ATR-
Chk1, FA, TLS, and HR pathways (Knipscheer et al, 2009). In addi-
tion, since TLS and HR require active DNA synthesis, genes
involved in dNTP production may also significantly impact ICL
repair. To address how these groups of genes might be affected by
HDAC inhibition, we treated cells with bendamustine, CY or HDAC
inhibitor SAHA, and compared the expression level of more than 50
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genes belonging to these aforementioned gene groups (Supplemen-
tary Tables S1 and S2) as well as many other genes that have been
reported to regulate DNA repair. Among these genes, we found that
the expression levels of three histone acetyltransferases Tip60, CBP,
and MORF, and MSL1, a gene associated with the histone acetyl-
transferases MOF (Smith et al, 2005; Huang et al, 2012), were all
greatly suppressed in CY-treated cells as early as 6 h (Fig 3A), and
such downregulation was not caused by drug-induced cell death
Bendamustine
CY
Compound A
Compound B
BA
C
DMSO       Bend          CpdA CpdA CY
+Bend
D
γ-H2AX
β-actin
40μm
Figure 1. The side chain structure of CY enhances nitrogen mustard activity in cancer cells.
A Chemical structures of bendamustine, CY, compound A, and compound B (referred to as Cpd A and Cpd B hereafter).
B Growth inhibitory concentration (GI50) of CY and bendamustine in the NCI60 cell line panel.
C Nontoxic dose of Cpd A enhances bendamustine cytotoxicity in cancer cells. Images were taken at 48 h posttreatment.
D Cpd A augments DNA damage caused by bendamustine. H1650 cells were treated with 100 lM Bend, 50 lM Cpd A, 100 lM Bend plus 50 lM Cpd A, or 10 lM CY for
12 h, and cell lysates were blotted for c-H2AX. Actin was used as a loading control.
Source data are available online for this figure.
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Figure 2. CY harbors HDAC inhibitory activity that enhances nitrogen mustard’s anticancer efficacy.
A Upper panel, in vitro HDAC1 inhibition assay using bendamustine and CY. Lower panel, summary of CY IC50 against other HDACs.
B CY and CpdA, but not bendamustine or CpdB, inhibited HDAC activities in cancer cells. H1650 cells were treated with 20 lM CY, 20 lM CpdA, 200 lM CpdB, 200 lM
Bend, or 10 lM SAHA for 12 h, and cell lysates were blotted for histone acetylation markers. Actin was used as a loading control.
C Molecular docking of CY with the structure of HDAC1/2 enzyme pocket.
D Alteration of CY side chain (Cpd B) caused loss of HDAC inhibitory activity and resulted in reduced ability to induce DNA damage. Cells were treated for 12 h. Cells
treated with 200 lM Cpd B and 20 lM CY exhibited similar levels of c-H2AX. Actin was used as a loading control.
E Summary of lethal dose 50 (LD50) of bendamustine, CY, Cpd A (HDAC inhibition only), and Cpd B (nitrogen mustard only) against 11 human cancer cell lines.
F Cpd A enhances the anticancer activity of bendamustine. H1650 cells were treated with various doses of bendamustine with or without 40 lM Cpd A (nontoxic dose,
see Fig 1C and Supplementary Fig S2) for 48 h and subjected to MTT viability assays.
Source data are available online for this figure.
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Figure 3. HDAC inhibition by CY leads to downregulation of several histone acetyltransferases involved in DNA repair.
A CY, but not bendamustine treatment, led to suppression of CBP, TIP60, MORF, and MSL1 in H1650 cells. Cells were treated with DMSO, bendamustine (350 lM),
CY (15 lM), or SAHA (10 lM) for 6 h, and mRNA was extracted for qPCR analysis. Data represent mean  SEM from three independent experiments, and statistical
significance was determined by unpaired two-tailed t-test. ***P < 0.01.
B Drug treatment up to 10 h at the concentrations indicated in (A) did not cause apoptosis as judged by PARP cleavage. Actin was used as a loading control.
C ShRNA-mediated suppression of CBP, TIP60, MORF, and MSL1 at mRNA level. Data represent mean  SEM from three independent experiments, and statistical
significance was determined by unpaired two-tailed t-test. *P < 0.1, **P < 0.05, ***P < 0.01.
D Suppression of CBP, TIP60, MORF, and MSL1 sensitized cells to bendamustine. Y-axis represents relative resistance calculated from results of GFP competition assays,
and statistical significance was determined by unpaired two-tailed t-test. Data represent mean  SEM from two independent experiments. **P < 0.05, ***P < 0.01.
Source data are available online for this figure.
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(Fig 3B). Tip60 has been reported to regulate ATM-mediated DNA
repair (Sun et al, 2005; Kaidi & Jackson, 2013), whereas CBP have
been shown to regulate ATR-Chk1 pathway and chromatin remodel-
ing at DNA lesions (Hasan et al, 2001; Stauffer et al, 2007). MSL1
has also been shown to affect DNA repair (Gironella et al, 2009;
Aguado-Llera et al, 2013). Importantly, shRNA suppression of these
four genes (Fig 3C, Supplementary Fig S3) each sensitized cells to
bendamustine (Fig 3D, Supplementary Tables S3 and S4). Of note,
suppression of these genes alone did not affect cellular viability
without drug treatment (Supplementary Fig S4). Taken together, our
data demonstrated that in addition to other reported mechanisms
(Miller et al, 2010; Robert et al, 2011), HDAC inhibition could
increase the potency of nitrogen mustards through downregulation
of genes that regulate DNA repair, including Tip60, CBP, MORF,
and MSL1. Our study of CY as a prototype of DNA/HDAC dual-
targeting drug demonstrates that by incorporating HDAC inhibitory
moiety into traditional DNA-damaging drugs, it is indeed possible to
achieve much higher toxicity against cancer cells.
Lastly, we studied the antitumor activity of this dual-targeting
drug in vivo. We first determined that the MTD (maximally tolerated
doses) of CY is 60 mg/kg in mice (Fig 4A). Next, we used a trans-
plantable BCR-ABL-driven acute lymphoblastic leukemia (ALL)
mouse model to assess CY’s in vivo activity. BCR-ABL-positive ALL
accounts for about 1/3 of adult human ALL cases and is tradition-
ally treated with many types of chemotherapeutics. Despite the use
of heavy chemotherapy regimen, patients with this disease have a
very poor survival rate (Stock, 2010). Treatment with targeted thera-
peutics that inhibit BCR-ABL, such as dasatinib, is an emerging ther-
apy approach for this disease (Yanada et al, 2009). We chose this
mouse model therefore in order to compare CY with a wide range of
traditional chemotherapeutics as well as targeted therapeutics in an
in vivo setting.
In cultured BCR-ABL ALL cells, CY is more active than benda-
mustine (Fig 4B). Mice transplanted with BCR-ABL cells died
around 12 days after the injection of 40,000 leukemia cells without
treatment (Fig 4C). Treatment with SAHA or bendamustine at MTD
extended survival by approximately 2 and 5 days, respectively. In
contrast, mice treated with CY showed average survival extension
of 14 days (Fig 4C). Moreover, when compared with other chemo-
therapeutic agents commonly used in BCR/ABL ALL human
patients, including cyclophosphamide, doxorubicin, cytarabine, and
vincristine, CY’s survival extension was also superior to these drugs
(Fig 4D). This indicated that the DNA/HDAC dual-targeting
approach confers better therapeutic outcome and may have possible
clinical advantages.
In both mouse models and human patients, BCR-ABL ALL can be
effectively managed by continuous administration of the BCR-ABL/
Src inhibitor dasatinib (Gruber et al, 2009; Boulos et al, 2011). In
addition, a recent report indicated potential efficacy of mTOR inhibi-
tor PP242 in BCR-ABL ALL mouse model (Janes et al, 2010). Next,
we compared CY’s efficacy with targeted therapeutics dasatinib and
PP242 in this ALL model. To access the long-term clinical benefit of
CY treatment, we developed a weekly CY treatment schedule that
was well tolerated. Consistent with existing report (Janes et al,
2010), daily treatment of the mTOR inhibitor PP242 extended the
mice survival by an average of 8 days (Fig 4E). In contrast, daily
doses of dasatinib extended the survival up to 2 months. Impor-
tantly, weekly doses of CY prolonged the survival to a similar extent
as dasatinib (Fig 4E), further demonstrating CY’s potent anticancer
effects in vivo. Lastly, in xenograft models using the human lung
cancer cell line H460, CY also showed potent anticancer activity that
was superior to bendamustine (Fig 4F and G). Taken together, these
data showed that the DNA/HDAC dual-targeting drug CY has potent
anticancer activity in vivo.
Given that bendamustine has shown significant clinical efficacies
in treating chronic lymphocytic leukemia (CLL), we further tested
CY’s efficacy in freshly isolated human CLL cells. CY killed nearly
all CLL cells at 5 lM. In contrast, bendamustine, and fludarabine,
another CLL frontline drug, at 100 lM could only kill about 80%
CLL cells (Fig 5A). Moreover, despite CY’s high efficacy in killing
CLL cells at 5 lM, healthy primary B cells still remain about 40%
viable after treatment with 20 lM CY (Fig 5B). These data show
that CY potently kills CLL cells, and there is a preferential killing of
transformed cells over healthy, non-transformed B cells.
In clinics, bendamustine is ineffective in treating CLL cells with
17p deletion. CLL cells harboring this deletion lose p53 and become
refractory to bendamustine treatment (Zaja et al, 2013). Interest-
ingly, CY kills 17p-deleted and 17p-retaining CLL cells with similar
efficacy (Fig 5C), suggesting that CY may represent a potential new
choice for exploring treatment strategies for 17p-deleted CLLs.
Discussion
In this report, we described the development and characterization of
CY, a bendamustine-derived, DNA/HDAC dual-targeting anticancer
drug. In our previous report (Jiang et al, 2011), we tested CY in
several cell lines and found it to exhibit significantly enhanced anti-
cancer activity in vitro; however, the source of such enhanced
activity remained undefined. One important question is whether
Figure 4. CY exhibited enhanced anticancer activity in vivo.
A Determination of maximally tolerated dose (MTD) of CY at 60 mg/kg. Other drugs were used at MTD according to the literature. For each drug, n = 5 and all mice
survived treatment. Data represent mean  SEM.
B CY exhibited enhanced activity against BCR-ABL Arf/ murine ALL cells in vitro.
C, D CY showed superior antitumor activity compared with bendamustine, SAHA, and other chemotherapeutic drugs in mice transplanted with BCR-ABL ALL cells.
P-values of CY versus other drugs: NT (P = 5.02E-06) (C), SAHA (P = 4.45E-06), Bend (P = 5.18E-06), NT (P = 1.20E-05) (D), VCR (P = 1.13E-05), Dox (P = 8.08E-06),
AraC (P = 7.62E-06), and CTX (P = 1.13E-05). Survival statistical analysis was done with the Mantel–Cox (log-rank) test of GraphPad Prism.
E Therapeutic effects of CY (weekly dose) and targeted drugs PP242 (daily dose) and dasatinib (daily dose) in mice transplanted with BCL-ABL ALL cells. P-values of CY
versus other drugs: NT (P = 3.94E-05), PP242 (P = 1.20E-05), and dasatinib (P = 0.99). Survival statistical analysis was done with the Mantel–Cox (log-rank) test of
GraphPad Prism.
F, G Antitumor activity of CY and bendamustine in nude mice models. Mice were inoculated with human NSCLC cell line H460. When tumor volume reached 200 mm3,
mice were treated with single dose of bendamustine (40 mg/kg, MTD) or CY (20, 40, 60 mg/kg). In (G), tumors were dissected out after 15 days posttreatment.
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there are generally applicable rules that we can derive from CY, so
that we can apply such rules to improve other existing anticancer
drugs. In this report, we dissected this phenomenon and provided
mechanistic explanation. Biochemically, CY is capable of both
inducing DNA damage and inhibiting HDACs (Figs 1D and 2B). In a
panel of 60 commonly used cancer cell lines, CY exhibited 50- to
100-fold increased activity compared to the parental compound
bendamustine. In vivo, CY also exhibited far-superior anticancer effi-
cacy compared to bendamustine. Given that bendamustine has
recently been shown to exert strong clinical activity in several types
of human malignancies, it should be interesting to test CY’s efficacy
in these disease settings.
One interesting question remains whether CY would be superior
to the combination treatment of bendamustine and HDAC inhibi-
tors. Due to both activities being tethered in the same molecule of
CY, it is possible that by delivering both DNA damaging and HDAC
inhibitory ability at the same time to tumor cells in vivo, CY may
work better than the combinatory treatment of bendamustine and
HDAC inhibitor, whose pharmacodynamics and pharmacokinetics
differ in vivo. Unfortunately due to the difference in treatment sche-
dule (bendamustine, single dose; SAHA, daily dose) and toxicity
issues, we could not establish an effective treatment schedule that
involves both bendamustine and SAHA. Considering that there is
currently no protocol using both bendamustine and SAHA in clinics
and that bendamustine is effective in several cancer types as a single
drug, we therefore focused on comparing the efficacy between CY
and bendamustine in vivo. Our results suggested that CY had signifi-
cantly enhanced in vivo anticancer activity compared to bendamus-
tine in several transplanted and xenograft cancer models. Moreover,
the BCR-ABL mouse ALL model enabled us to compare the efficacy
of CY with several other commonly used anticancer drugs. Our
results showed that CY has superior anticancer activity over several
first-line chemotherapeutic drugs, and in this model CY’s efficacy is
even comparable to the targeted drug, BCR-ABL inhibitor dasatinib.
Taken together, the data suggested that this novel DNA/HDAC dual-
targeting drug CY has significant anticancer efficacy in vivo.
Although HDAC inhibitors have been investigated as radio-
sensitizing agents (Ree et al, 2010), the complete picture of HDAC
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Figure 5. CY exhibited activity with CLL samples.
A Dose curve of CY, fludarabine, and bendamustine using fresh CLL samples. Data represent mean  SD.
B CY preferentially killed CLL cells over healthy B cells. Data represent mean  SD.
C Toxicity of CY190602 in patients harboring deletion of chromosome 17p (including p53 locus) compared to patients without del17p. Viability of samples was normalized
to background apoptosis for individual patient samples. For all experiments, cell viability was determined after 72 h of drug treatment. Data represent mean  SD.
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in DNA repair remained elusive. Several recent publications shed
light on this topic and suggested that HDAC may function directly at
sites of DNA damage by altering local histone code (Miller et al,
2010; Robert et al, 2011). In addition, a recent proteomic study
found that many DNA repair proteins including MDC1, BLM, and
Rad50 are modified by acetylation after HDAC inhibition
(Choudhary et al, 2009). It is possible that HDAC inhibition may
negatively impact the stability and/or activity of these repair
proteins. For example, it was shown that upon HDAC inhibition, the
HR nuclease Sae2/CtIP is acetylated and degraded (Robert et al,
2011). In addition, HDAC inhibition can suppress the ATM signaling
pathway, thereby sensitizing cancer cells to DNA damage (Thurn
et al, 2013).
In this report, we focused on HDAC’s role in DNA repair by
demonstrating its rapid transcriptional control of other groups of
important DNA repair genes. We examined gene expression level
after 6-h treatment with CY or SAHA in multiple types of cancer
cell lines. Interestingly, among genes whose expression is signifi-
cantly suppressed upon HDAC inhibition, Tip60, CBP, MORF, and
MSL1 are all histone acetyltransferases or histone acetyltransferase-
associated protein, and shRNA suppression of these genes sensitized
cells to DNA damage. Moreover, we also found that upon HDAC
inhibition, another histone acetyltransferase EP300, and TYMS, a
gene involved in nucleotide synthesis, are both transcriptionally
downregulated upon HDAC inhibition (Supplementary Fig S5),
and shRNA suppression of either gene by itself is lethal to cancer
cells even without DNA damage (Supplementary Fig S6). Because
cells with TYMS or EP300 shRNAs were rapidly eliminated in cell
culture, we could not analyze whether loss of these two genes
further sensitized cells to DNA damage. However, given their
important roles in nucleotide pool maintenance and DNA repair
(Hasan et al, 2001), it is rather possible that downregulation of
these two genes upon HDAC inhibition could cause further impair-
ment in DNA repair.
Of note, previous reports have suggested that BRCA1 and the
NHEJ repair genes Ku70, Ku80, and DNAPKcs are suppressed by
HDAC inhibitors (Zhang et al, 2007, 2009). In our hand, unlike the
case for Tip60, CBP, MORF, MSL1, and EP300, suppression of
BRCA1, Ku70, Ku80, and DNAPKcs did not occur at 6 h upon HDAC
inhibition, suggesting that it may not be an early response upon
HDAC inhibitor treatment. To further examine this discrepancy, we
searched the connectivity map (Lamb et al, 2006), a consortium of
microarray data, and identified 12 microarray datasets from cells
treated by HDAC inhibitors. Importantly, none of the previously
reported genes (BRCA1, Ku70, Ku80, and DNAPKcs) were among
the top 200 downregulated genes in any of these HDAC inhibitor-
treated cells. In contrast, Tip60, CBP, MORF, MSL1, and EP300 were
among the top 200 downregulated genes in 5, 6, 11, 9, and 5 of the
12 HDAC inhibitor-treated cells, suggesting that this is a highly
potent and consistent effect of HDAC inhibitors. Importantly, given
our finding that HDAC inhibition caused rapid and significant
downregulation of these histone acetyltransferases or histone
acetyltransferase-associated protein, it is possible that upon HDAC
inhibition, a transcriptional feedback mechanism is activated to
downregulate cellular acetyltransferase activity, which subsequently
caused impairment of cellular DNA repair capacity. This may
constitute a major transcription-related mechanism that contributes
to HDAC inhibitor-mediated repression of DNA repair.
Given the potent lethality of irreparable DNA strand breaks,
approaches to suppressing DNA repair have been intensively inves-
tigated, as they may bring significant benefits to cancer therapy. The
recent success of PARP inhibitors in treating BRCA-deficient tumors
showcases the therapeutic potential of such approach. Inhibitors of
kinases with long-established roles in DNA repair, such as ATM,
ATR, and DNAPKcs, are in various stages of preclinical and clinical
investigations for their potential benefits in improving traditional
chemotherapy. Moreover, with the recent advances in our under-
standing of DNA repair, several additional groups of enzymes have
been recognized for their involvement of DNA repair, including
HDACs (Miller et al, 2010; Robert et al, 2011), histone acetyltransfe-
rases (Sun et al, 2009; Niida et al, 2010), ubiquitin ligases (Kolas
et al, 2007; Stewart et al, 2009), deubiquitinases (Nakada et al,
2010), SUMO ligases (Galanty et al, 2009; Morris et al, 2009), and
histone methyltransferases (Liu et al, 2010). Pharmacological target-
ing of these enzymes may also enhance the efficacy of traditional
genotoxic anticancer drugs. Our study of CY as a prototype of DNA/
HDAC dual-targeting drug demonstrates that by incorporating small
enzyme inhibitory moiety into traditional DNA-damaging drugs, we
can achieve higher toxicity against cancer cells. Importantly, our
result showed that it is structurally compatible to incorporate small
enzyme inhibitory chemical moieties into DNA damage drugs, and
such modifications can significantly enhance nitrogen mustard’s
anticancer activity. On the basis of this rationale, we have devel-
oped a novel nitrogen mustard derivative that targets both DNA and
CDK, and it also showed about 100-fold increases in anticancer effi-
cacy. This suggests that it may be generally applicable to incorpo-
rate various enzyme inhibitory moieties into traditional genotoxic
drug to achieve better efficacy. Taken together, it is interesting to
develop other types of HDAC/DNA dual-targeting drugs, as well as
other types of drugs that target both DNA and some of the enzymes
involved in DNA repair. Such drugs may by itself improve cancer
treatment, and their much-improved anticancer efficacy also offers
new possibilities for antibody-coupled, tumor-targeted drug delivery
research. This may provide several novel categories of anticancer
drugs for clinical investigation.
Materials and Methods
Cell culture and reagents
Cell lines were cultured using standard protocols provided by ATCC.
Myc Arf/ cells were cultured as described (Jiang et al, 2009).
BCR-ABL mouse ALL cells were a kind gift from Dr. Richard
Williams. CY190602 and its derivatives compound A and B were
synthesized by Dr. Wang’s Laboratory (U. New Mexico). Other
chemicals were purchased from Selleck, EMD, or VWR. Antibodies
against c-H2AX (Millipore), actin (Sigma), H3K18Ac, H3K9Ac, and
H3K56Ac (Cell Signaling) were used for Western blotting.
shRNA construct cloning, RNA preparation and qPCR
Retroviral pMSCV-IRES-GFP vector and the cloning procedures have
been previously described (Jiang et al, 2009, 2011). Target-gene
knockdown efficiency was analyzed by qPCR. Total mRNA of cells
was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
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according to the manufacturer’s instruction. Total mRNA was tran-
scribed to cDNA with the SuperScriptIII First-Strand Synthesis
System (Invitrogen, Carlsbad, CA, USA).
Cell viability assays and determination of relative drug resistance
Cells were seeded in 96-well plates, treated with different concentra-
tions of drugs for 48 h, and cell viability was analyzed by MTT
assays according to manufacturer’s protocols. Experiments to deter-
mine GI50 with the NCI60 panel cell lines (http://dtp.nci.nih.gov/
branches/btb/ivclsp.html) were performed at NCI (Alley et al, 1988;
Shoemaker, 2006).
To test how shRNA suppression of certain genes affects cellular
sensitivity to drugs, we used a GFP-based competition experimental
system previously described by Jiang et al (Jiang et al, 2011).
Briefly, shRNA and GFP were stably transduced into cells via retro-
viral vectors; therefore, cells in which targeted genes were knocked
down also express GFP. A mixture of knockdown cells (GFP posi-
tive) and control cells (no viral infection, GFP negative) was treated
with drugs. If knockdown of target gene sensitizes cells to drug,
then in the survival cell population, the percentage of GFP-positive
(gene knockdown) cells will decrease. By comparing GFP percent-
ages with and without drug treatment, we can calculate relative
resistance or sensitivity caused by target-gene knockdown, using a
method previously described.
Mouse experiments
Experimental procedures were approved by the Animal Care and
Use Committee of Shanghai Institute of Biochemistry and Cell Biol-
ogy, Chinese Academy of Sciences. In all, 200 wild-type C57BL/6
mice (6 weeks old, female) were used for determining maximally
tolerated dose of CY, and testing CY and other drugs’ efficacy in the
BCR-ABL ALL model. BCR-ABL cells have been previously described
(Williams et al, 2006). For in vivo experiments, 1 million cells were
injected into mice via tail vein (Williams et al, 2006). At 7 days
postinjection, mice were treated with indicated drugs at their MTDs.
Mice were monitored daily for survival after drug treatment.
Survival curve and statistical analysis were done using the Prism
software. For xenograft H460 model, in all, nude mice (8 weeks old,
female) were used to test CY and bendamustine’s in vivo efficacy.
The numbers of mice used in each experimental group are labeled
on Fig 4.
CLL patients and cells
This study was approved by the ethics committee of the University
of Cologne (approval 01-163). Blood samples were obtained from
patients fulfilling diagnostic criteria for CLL with informed consent
according to the Helsinki protocol. Only patients without prior ther-
apy or at least 12 months without prior chemotherapy were
included in this study. Fresh blood samples were enriched by apply-
ing B-RosetteSep (StemCell Technologies, Vancouver, Canada) to
aggregate unwanted cells with erythrocytes and Ficoll-Hypaque
(Seromed, Berlin, Germany) density gradient purification resulting
in purity > 98% of CD19+/CD5+ CLL cells. CLL cells were charac-
terized for CD19, CD5, CD23, FMC7, CD38, ZAP-70, slgM, slgG,
CD79a, and CD79b expression on a FACSCanto flow cytometer (BD
PharMingen, Heidelberg, Germany). Controls were isolated from
healthy blood donors using anti-CD19 MACS beads (Miltenyi, Berg-
isch Gladbach, Germany) resulting in at least 95% CD19+ B cells.
Apoptosis and cell viability assays
Apoptosis was determined by flow cytometry using Annexin
V-FITC/7AAD staining (BD PharMingen) after 72 h. The cellular
potency of compounds as defined by half-maximal induction of
apoptosis in primary CLL cells was determined using concentrations
up to 100 lM. The fraction of viable cells was determined by count-
ing annexin V/7-AAD double-negative cells for each individual
dosage. Median values were subsequently applied for regression
analysis and calculation of the half-maximal dosage effect (IC50).
Curve fitting was performed using SigmaPlot (SPSS, Chicago). IC50
values were determined by fitting data to the Hill equation
y = y0 + (axb)/(cb+xb).
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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The paper explained
Problem
Most existing anticancer drugs attack single targets in cancer cells,
which, however, activate various strategies to repair the damage
induced by the drugs or to counter their efficacy. This significantly
limits the efficacy of existing drugs and can cause treatment failure
and illustrates the need for developing novel, more potent anticancer
drugs.
Results
We developed and characterized a novel dual-targeting drug based
on side chain modification of the nitrogen mustard drug bendamus-
tine, with high potency against cancer. This drug not only attacks
DNA, but also inhibits HDACs, a group of enzymes important for DNA
repair, so that cancer cells cannot readily repair the damage it causes.
We also show that this dual-targeting drug has significantly improved
efficacy over drugs that have single targets in many cancer cell lines
and various cancer mouse models.
Impact
Our results indicate that by incorporating two cooperating anticancer
chemical groups into the same compound, dual-targeting drugs with
higher efficacy can be generated. This approach can therefore be used
to systematically increase the potency of traditional DNA-damaging
drugs. Such dual-targeting drugs may provide new categories of anti-
cancer drugs for cancer treatment.
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